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Objectives: This study was undertaken to examine recent trends
in the use of angiotensin-converting enzyme (ACE) inhibitor
therapy in patients discharged after acute myocardial infarction
(AMI) and to identify clinical factors associated with ACE inhib-
itor prescribing patterns.
Background: Clinical trials have demonstrated a significant
mortality benefit in patients treated with ACE inhibitors after
AMI. Numerous studies have demonstrated underuse of other
beneficial treatments for patients with AMI, such as beta-
adrenergic blocking agents, aspirin and immediate reperfusion
therapy.
Methods: Demographic, procedural and discharge medication
data from 190,015 patients with AMI were collected at 1,470 U.S.
hospitals participating in the National Registry of Myocardial
Infarction 2.
Results: Prescriptions for ACE inhibitor therapy at hospital
discharge increased from 25.0% in 1994 to 30.7% in 1996. Patients
with a left ventricular ejection fraction <240% or evidence of
congestive heart failure while in the hospital were discharged with
ACE inhibitor treatment 42.6% of the time. Of patients experienc-
ing an anterior wall myocardial infarction and no evidence of
heart failure, 26.1% of patients were discharged with this treat-
ment. Of the remaining patients, 15.6% received ACE inhibitors at
discharge. ACE inhibitors were prescribed more often to elderly
and diabetic patients as well as those requiring intraaortic
balloon pump placement. This therapy was given less often to
patients who underwent revascularization with coronary angio-
plasty or coronary artery bypass graft surgery or were treated with
calcium channel blocking agents.
Conclusions: Physicians are prescribing ACE inhibitors in
patients with myocardial infarction with increasing frequency.
Those patients with the greatest expected benefit receive ACE
inhibitor treatment most often. However, the majority of even
these high risk patients were not discharged with this life-saving
therapy.
(J Am Coll Cardiol 1998;32:360–7)
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Since the early 1980s when treatment with angiotensin-
converting enzyme (ACE) inhibitors was shown to reduce
myocardial infarction size and improve ventricular remodeling
(1–6), .100,000 patients have been enrolled in randomized
studies investigating the role of ACE inhibitors after myocar-
dial infarction. Initially, ACE inhibitors were shown (7) to have
a beneficial effect on symptoms and mortality in patients with
severe congestive heart failure. This observation led to other
studies demonstrating similar findings in postinfarction pa-
tients with less severe congestive heart failure (VHEFT II [8],
SOLVD [9], AIRE [10], TRACE [11]) and asymptomatic left
ventricular systolic dysfunction (SAVE [12]). More recent
randomized trials have shown an additional mortality benefit
when ACE inhibitor therapy is begun within 24 h of myocardial
infarction (GISSI-3 [13], ISIS-4 [14], CCS-1 [15], SMILE [16]).
Current American College of Cardiology (ACC) and Ameri-
can Heart Association (AHA) practice guidelines (17) state
that oral ACE inhibitors should be started within the first 24 h
of suspected acute myocardial infarction (AMI) and continued
for 4 to 6 weeks in those patients without contraindications. In
patients with left ventricular dysfunction, this therapy should
be continued for at least 3 years (18).
To evaluate the impact of these clinical trials on physician
practice patterns, we examined data from the National Registry of
Myocardial Infarction 2, a large registry of patients with an AMI
who were treated at selected U.S. hospitals. Specifically, we
sought to determine whether there was a temporal increase in the
use of ACE inhibitors at hospital discharge. In addition, we
investigated which clinical characteristics were predictive of pa-
tients receiving ACE inhibitor treatment and whether particular
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patient groups with a greater absolute expected benefit from
ACE inhibitors were more likely to receive this life-saving
therapy.
Methods
Data sources. The National Registry of Myocardial Infarc-
tion 2 (NRMI 2) is a prospective, observational study spon-
sored by Genentech, Inc. (South San Francisco, California).
NRMI 2, which was initiated in June 1994, contains data
abstracted from the charts of patients with AMI admitted to
registry hospitals. The completed case report form is for-
warded from the registry hospital to an independent central
data collection center (ClinTrials Research, Inc., Lexington,
Kentucky) for processing and analysis.
The study coordinator from each participating hospital
attended a half-day training course and was provided with a
reference manual that included case report form definitions
and examples of how to correctly complete the form. The data
collection center used double-key entry to add data from each
case report form to the database. Eight-seven electronic data
checks were performed to detect internal inconsistencies,
omissions, errors and out-of-range variables. National and
periodic regional meetings of study coordinators and physician
investigators were held to discuss data management issues. A
quarterly study newsletter was also used to address these
issues.
Additional data was collected in a subset of patients who
were included in both the NRMI 2 and the national Cooper-
ative Cardiovascular Project (CCP), a study sponsored by the
Health Care Financing Administration (HCFA) to improve
care for Medicare beneficiaries admitted to the hospital with
AMI. The CCP file contains two creatinine variables—a base-
line value and a highest recorded value—that were not in-
cluded in NRMI 2. Acute care hospitals registered in the CCP
from across the United States submitted 24,377 medical
records for patients with AMI admitted to the hospital within
specified 8-month periods between March 1, 1994 and June 30,
1995. The standardization and matching process to integrate
the two databases has been described in detail (19). The final
matched NRMI 2/CCP population included 1,076 providers
and 25,664 patient-episodes.
Study definitions. The method of diagnosis of AMI was
defined by the study protocol as 1) a patient history and
presentation suggestive of AMI accompanied by either a) total
creatinine kinase greater than or equal to twice the upper limit
of hospital laboratory normal or creatinine kinase-MB fraction
greater than or equal to the upper limit of hospital laboratory
normal, or b) electrocardiographic (ECG) evidence of AMI, or
c) in the absence of definitive/available cardiac enzyme or
ECG data, alternative enzymatic, scintigraphic, echocardio-
graphic, angiographic or autopsy evidence indicative of AMI;
or 2) an International Classification of Diseases, 9th revision,
clinical modification, discharge diagnosis code for AMI, 410.01
through 410.91.
Killip class was assigned to patients on the basis of their
most severe symptoms of heart failure at first assessment. Killip
Class I was defined as the absence of rales in the lung fields and
the absence of an S3 heart sound; Killip class II was defined as
rales ,50% of the lung fields, the presence of an S3 heart
sound or jugular venous distention; Killip class III was defined
as rales .50% of the lung fields; and Killip class IV was defined
as the presence of pulmonary edema with hypotension.
All registry patients were classified into three mutually
exclusive groups according to the degree of expected absolute
benefit for treatment with ACE inhibitors. The first group of
patients was categorized as having the greatest expected
absolute benefit for ACE inhibitor therapy. These patients
were defined as having a measured left ventricular ejection
fraction (LVEF) #40% or evidence of congestive heart failure
during the hospital period. The second group of patients
included those with an intermediate expected absolute benefit
from ACE inhibitor therapy: patients with anterior myocardial
infarction and no evidence of congestive heart failure. The
third group included all remaining patients in the registry.
In addition, detailed demographic data were collected and
included age, gender, race, weight and additional medical
Abbreviations and Acronyms
ACC 5 American College of Cardiology
ACE 5 angiotensin-converting enzyme
AHA 5 American Heart Association
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
CCP 5 Cooperative Cardiovascular Project
ECG 5 electrocardiographic
LVEF 5 left ventricular ejection fraction
NRMI 2 5 National Registry of Myocardial Infarction 2
PTCA 5 percutaneous transluminal coronary angioplasty
Table 1. Baseline Demographic and Clinical Characteristics by
Angiotensin-Converting Enzyme Inhibitor Treatment at Discharge
Characteristic
Therapy at
Discharge
(n 5 52,668)
No Therapy
at Discharge
(n 5 137,347)
Demographic
Age (yr) 68.5 6 13.2 65.5 6 13.7
Women 41.3% 35.8%
African-American 7.7% 6.4%
Past medical history
Diabetes mellitus 32.3% 22.2%
History of hypertension 58.1% 46.6%
Current tobacco use 24.6% 31.1%
History of stroke 9.2% 6.6%
Prior coronary angioplasty 7.5% 7.8%
Prior coronary artery bypass graft surgery 13.2% 10.2%
History of congestive heart failure 20.1% 8.8%
History of angina 19.8% 17.6%
Previous myocardial infarction 30.4% 22.4%
Data presented are mean value 6 SD or percent of patients.
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history variables as listed in Table 1. Presenting characteristics
of patients included the time from symptom onset to hospital
arrival, blood pressure and heart rate on admission as well as
Killip class (Table 2). The location and type of AMI were
designated, as was the occurrence of clinical events, such as
hypotension, recurrent ischemia or infarction, pulmonary
edema, cardiogenic shock, ventricular fibrillation and death.
LVEF and its method of determination were recorded for
those patients with known values. For patients with multiple
measurements, the value measured closest to discharge was
listed. The use of medications within 24 h of diagnosis was
noted, as was the use of selected procedures during the
hospital period (Table 3). Finally, medications prescribed at
hospital discharge were indicated.
Registry hospitals were classified according to registration
data on enrollment into NRMI 2. Hospitals were asked to
indicate on enrollment whether they had the capability to
perform cardiac catheterization, angioplasty or open heart
surgery, alone or in combination. Hospitals were defined as
“urban” if they were located in a county that had at least one
city with .50,000 persons or twin cities with a combined
population of 50,000 persons. The primary payer of hospital
charges was identified as commercial, paid provider organiza-
tion, health maintenance organization, Medicare, Medicaid,
Department of Veterans Affairs, self, other or unknown.
Analysis. Baseline demographics, clinical events, use of
medications and utilization of cardiac procedures were com-
pared. Statistical differences were calculated between NRMI 2
and CCP. These analyses were performed in the matched
NRMI 2/CCP population and among the NRMI 2 and CCP
comparison populations. A regression analysis was then per-
formed on each comparison population to determine whether
associations existed between the health indexes and mortality.
Statistical methods. Chi-square and Student t tests were
performed to determine whether differences existed within
baseline characteristics, therapy and procedures of the com-
parison databases and matched database. A stepwise logistic
regression model was developed to identify predictors of
receiving ACE inhibitor therapy at discharge. The model
included all variables shown in Tables 1 to 3, except time and
was run for each of the three levels of expected benefit from
ACE inhibitor use. After all variables entered the model, the
time variable was included in the analysis to assess its associ-
ation with ACE inhibitor use. Odds ratios and 95% confidence
intervals are reported for each model (Tables 4 to 6). Logistic
regression was utilized to determine correlation of in-hospital
mortality and health indexes. All statistical calculations were
performed with the SAS 6.12 statistical procedure (SAS Insti-
tute).
Time, the major independent variable, was defined in two
ways: 1) For univariate analysis, the 25-month study period was
divided into quartiles. 2) In the multivariate analysis, time was
defined as the number of days from June 1, 1994 to hospital
discharge. The major dependent variable used in this study was
Table 2. In-Hospital Characteristics by Angiotensin-Converting
Enzyme Inhibitor Treatment at Discharge
Characteristic
Therapy at
Discharge
(n 5 52,668)
No Therapy
at Discharge
(n 5 137,347)
Time from symptom onset to hospital
arrival (h)
5.9 6 9.9 5.5 6 9.2
Systolic blood pressure
,90 mm Hg 2.9% 3.0%
90–180 mm Hg 82.8% 85.6%
.180 mm Hg 14.3% 11.4%
Admission heart rate
,50 beats/min 2.5% 3.2%
50–100 beats/min 69.3% 79.4%
.100 beats/min 28.2% 17.4%
Anterior myocardial infarction 37.2% 23.5%
Q wave myocardial infarction 53.2% 51.3%
Left ventricular ejection fraction ,45% 59.0% 28.7%
Killip class
I (no CHF) 64.4% 82.2%
II (rales, JVD) 22.9% 12.4%
III (pulmonary edema) 11.8% 4.9%
IV (cardiogenic shock) 0.9% 0.5%
In-hospital clinical events
Hypotension 12.3% 11.1%
Recurrent ischemia 13.1% 12.6%
Recurrent infarction 2.4% 2.1%
Pulmonary edema 26.7% 11.3%
Cardiogenic shock 3.2% 1.6%
VT/VF 6.7% 5.1%
Data presented are mean value 6 SD or percent of patients. CHF 5
congestive heart failure; JVD 5 jugular venous distention; VT/VF 5 ventricular
tachycardia/ventricular fibrillation.
Table 3. In-Hospital Therapy by Angiotensin-Converting Enzyme
Inhibitor Treatment at Discharge
Characteristic
Therapy at
Discharge
(n 5 52,668)
No Therapy
at Discharge
(n 5 137,347)
Admission medications
Thrombolytic use 24.9% 29.3%
Aspirin 75.1% 77.9%
Beta-blocker 37.7% 41.4%
ACE inhibitor 38.5% 5.6%
Heparin 74.6% 77.6%
Calcium blocker 19.9% 21.5%
Procedures
Coronary angiography 56.3% 65.2%
Coronary angioplasty 23.3% 29.4%
Intraaortic balloon pump 7.1% 4.6%
Coronary artery bypass 10.3% 15.2%
Echocardiography 59.0% 45.3%
Discharge medications
Aspirin 70.6% 76.7%
Beta-blocker 38.7% 47.9%
Calcium blocker 19.2% 30.5%
Digoxin 34.1% 17.7%
Data presented are percent of patients. ACE 5 angiotensin-converting
enzyme.
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whether ACE inhibitors were prescribed at hospital discharge.
Because the number of patients in this study was so large,
assessing whether differences were statistically significant was
not informative. Hence, p values were not reported for the
univariate comparisons.
Results
Patient characteristics. From June 1, 1994 to June 30,
1996, we identified 275,560 patients with AMI from 1,470
hospitals in NRMI 2. Of these patients, 55,010 (20.0%) were
transferred out of registry hospitals, and thus the discharge
medications were unknown. These patients were excluded
from the analysis. In addition, 27,941 patients (10.1%) died
during the hospital period and were also excluded from the
study. The resultant 192,609 patients made up the main study
cohort. The mean age of patients included in the study was 66.6
years, and 62.5% were male. Information on the use of ACE
inhibitors was available for 190,015 patients (98.6%). Other
baseline demographic and clinical characteristics are shown in
Table 1. The final matching process integrating the CCP
database resulted in 25,664 cases (mean age 77 6 7 years; 49%
women).
Univariate analysis. In the first group of patients catego-
rized with the greatest absolute benefit for ACE inhibitor
therapy (i.e., LVEF #40% or evidence of congestive heart
failure [n 5 75,173]), 42.6% were prescribed ACE inhibitors
Figure 1. Discharge ACE inhibitor use by clinical indication group.
Table 4. Predictors of Discharge Angiotensin-Converting Enzyme
Inhibitor Use in Group 1: Treatment “Definitely” Indicated
Variable
Odds Ratio
(lower–upper
95% CI)
Diabetes mellitus 1.16 (1.13–1.20)
History of hypertension 1.21 (1.17–1.25)
History of CHF 1.28 (1.23–1.33)
Previous myocardial infarction 1.19 (1.15–1.23)
Systolic BP (per 20-mm Hg increase) 1.02 (1.01–1.03)
Heart rate (per 10-beats/min increase) 1.03 (1.02–1.04)
Anterior myocardial infarction 1.56 (1.51–1.61)
LVEF*
#40% 1.93 (1.85–2.03)
Unknown 1.24 (1.18–1.31)
Killip class .I 1.10 (1.08–1.11)
Hypotension 0.90 (0.86–0.94)
CHF/pulmonary edema 1.47 (1.43–1.52)
Admission calcium blocker 0.78 (0.75–0.81)
No. of discharge medications 1.10 (1.08–1.11)
Coronary angiography 1.17 (1.12–1.22)
Coronary angioplasty 0.82 (0.78–0.86)
Intraaortic balloon pump 1.54 (1.44–1.65)
In-hospital coronary artery bypass 0.46 (0.43–0.48)
Echocardiography 1.22 (1.18–1.27)
Time from 6/1/94 to admission (per 180-day increase) 1.07 (1.06–1.09)
*.40% is reference category. BP 5 blood pressure; CI 5 confidence
interval; LVEF 5 left ventricular ejection fraction; other abbreviations as in
Table 2.
Table 5. Predictors of Discharge Angiotensin-Converting Enzyme
Inhibitor Use in Group 2: Treatment “Probably” Indicated
Variable
Odds Ratio
(lower–upper
95% CI)
Diabetes mellitus 1.29 (1.20–1.39)
History of hypertension 1.56 (1.47–1.66)
History of CHF 1.69 (1.46–1.96)
Heart Rate (per 10-beats/min increase) 1.05 (1.03–1.06)
Non-Q wave myocardial infarction 0.67 (0.63–0.71)
Intraaortic balloon pump 1.81 (1.59–2.05)
In-hospital coronary artery bypass 0.49 (0.44–0.54)
Echocardiography 1.43 (1.35–1.52)
Admission calcium blocker 0.80 (0.74–0.87)
Time from 6/1/94 to admission (per 180-day increase) 1.11 (1.08–1.15)
Abbreviations as in Tables 2 and 4.
Table 6. Predictors of Discharge Angiotensin-Converting Enzyme
Inhibitor Use in Group 3: Treatment “Possibly” Indicated
Variable
Odds Ratio
(lower–upper
95% CI)
Age (per 10-yr increase) 1.07 (1.05–1.09)
Diabetes mellitus 1.47 (1.41–1.54)
History of hypertension 2.00 (1.92–2.08)
History of tobacco use 0.90 (0.86–0.95)
History of stroke 1.19 (1.11–1.28)
Prior coronary artery bypass 1.40 (1.32–1.49)
History of CHF 2.58 (2.39–2.78)
Previous myocardial infarction 1.31 (1.25–1.37)
Systolic BP (per 20-mm Hg increase) 1.09 (1.07–1.10)
Heart Rate (per 10-beats/min increase) 1.03 (1.02–1.04)
Intraaortic balloon pump 1.65 (1.48–1.85)
In-hospital coronary artery bypass 0.70 (0.66–0.75)
Echocardiography 1.21 (1.16–1.26)
Admission calcium blocker 0.86 (0.82–0.91)
Number of discharge medications 0.95 (0.94–0.97)
Time from 6/1/94 to admission (per 180-day increase) 1.11 (1.09–1.14)
Abbreviations as in Tables 2 and 4.
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(Fig. 1). Of those patients in the second group with an
intermediate expected benefit (i.e., anterior infarction with no
evidence of congestive heart failure [n 5 26,209]), 26.1%
received treatment, whereas 15.6% of the patients in the third
group (n 5 88,633) of remaining patients were prescribed ACE
inhibitors. Patients prescribed ACE inhibitors at discharge
were significantly older, with an average age of 68.5 years
compared with 65.5 years for patients not treated with ACE
inhibitors (Table 1). Women were more likely to be treated
with ACE inhibitors, as were patients with diabetes mellitus,
hypertension and a history of previous myocardial infarction or
congestive heart failure. Patients with tachycardia on admis-
sion as well as those discharged with a diagnosis of anterior
myocardial infarction were more likely to receive ACE inhib-
itor therapy. Of the 114,149 patients undergoing left ventricu-
lar function assessment, 59% of patients discharged with ACE
inhibitors had an LVEF ,45% compared with only 29% not
treated with ACE inhibitors at hospital discharge. Similarly,
patients with evidence of jugular venous distention, pulmonary
edema and cardiogenic shock on admission were roughly twice
as likely to be discharged with ACE inhibitors. Patients
undergoing coronary angiography, percutaneous transluminal
coronary angioplasty (PTCA) or coronary artery bypass graft
(CABG) surgery were all less likely to receive ACE inhibitor
treatment.
Multivariate analysis. To evaluate which clinical, demo-
graphic and hospital-related factors independently influenced
the use of ACE inhibitor therapy at the time of discharge, we
constructed a series of multivariate logistic regression models.
Independent predictors of ACE inhibitor therapy in the pa-
tients with the greatest expected absolute benefit for ACE
inhibitor use included anterior myocardial infarction, LVEF
#40%, congestive heart failure during hospitalization, Killip
class .I and previous history of diabetes mellitus, congestive
heart failure, myocardial infarction and hypertension (Table
4). Patients discharged with a diagnosis of anterior myocardial
infarction had a 54% increased odds of receiving ACE inhib-
itors at hospital discharge compared with patients who had a
myocardial infarction in any other location. The use of calcium
channel blockers at hospital discharge was associated with a
decreased odds of receiving ACE inhibitor treatment. Further-
more, there was a direct relation between the number of
discharge medications and the odds of being discharged with
an ACE inhibitor. Revascularization with PTCA or CABG was
also associated with decreased use of ACE inhibitor therapy.
When a time variable was introduced into the model, there was
evidence that ACE inhibitors were being used more commonly
in 1996 than in 1994. There was a 7% increase in the likelihood
of use of ACE inhibitors for each 180-day increment.
For those patients with an intermediate expected absolute
benefit for ACE inhibitor therapy, the significant independent
predictors of receiving therapy included a history of diabetes
mellitus, congestive heart failure and hypertension (Table 5).
Patients who underwent CABG were less likely to receive ACE
inhibitors, as were patients treated with calcium channel
blockers. There was also a temporal relation with an 11%
increased odds of ACE inhibitor treatment with each 180-day
increment.
For patients in group three comprising all remaining pa-
tients with a possible indication for ACE inhibitor treatment,
the independent predictors identified by the logistic regression
analysis included a history of diabetes mellitus, congestive
heart failure, hypertension, myocardial infarction and prior
CABG (Table 6). Patients who underwent revascularization
with PTCA or CABG during the present hospital period were
less likely to receive ACE inhibitors, as were patients treated
with either calcium channel or beta-blockers. Intraaortic bal-
loon pump placement was also predictive of increased ACE
inhibitor use. Similar to the second group in the model, there
was an 11% increased odds of ACE inhibitor use during each
180-day period.
Table 7 shows ACE inhibitor use at discharge by levels of
baseline and peak serum creatinine for the three groups. There
was a significant association between less ACE inhibitor use
when serum creatinine exceeded 2.0 either at baseline or at any
time during the hospital period.
Temporal trends in use of ACE inhibitors. The use of ACE
inhibitors in patients discharged after hospital admission for
AMI increased by 22.8% in the 25-month period studied. From
June 1, 1994 to December 31, 1994, 25.0% of patients received
ACE inhibitors compared with 30.7% from January 1, 1996 to
June 30, 1996 (Fig. 2). There was no clinically significant
change in the use of digoxin over the study period (range
21.8% to 22.6%). Calcium channel blocker use decreased by
27.6%. For each 180-day period, there was a 7%, 11% and
Figure 2. Discharge ACE inhibitor (squares) and calcium channel
blocker (circles) use by time period.
Table 7. Baseline and Highest Creatinine and Angiotensin-
Converting Enzyme Inhibitor Use at Discharge
Indication
Baseline mg/dl Peak mg/dl
#2.0 .2.0 #2.0 .2.0
Definite 43.9% 30.5%* 44.7% 35.0%*
Probable 25.8% 20.8% 25.7% 24.0%
Possible 17.6% 20.4% 17.5% 21.8%†
*p , 0.0001. †p 5 0.008.
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11% increased odds of receiving an ACE inhibitor in the
clinical indication groups one, two and three, respectively,
derived from the multivariate analysis.
Discussion
In our analysis of ACE inhibitor use in patients discharged
from NRMI 2 hospitals after myocardial infarction, we made
several observations.
1. We observed that clinicians prescribe ACE inhibitors
more aggressively in patient groups where such therapy is likely
to result in a greater absolute benefit, a pattern not seen with
beta-blocker use after AMI (20). In the present study, patients
with congestive heart failure or LVEF #40% during the
hospital period were categorized as a group with the greatest
expected benefit from ACE inhibitor treatment. Randomized
trials (1–16) have shown that these patients have a significantly
greater absolute mortality benefit when given ACE inhibitors
after myocardial infarction. Our data reveal that although
overall only 27.6% received ACE inhibitors at hospital dis-
charge, 42.6% of patients in the first group with the greatest
expected benefit for ACE inhibitors received such treatment
(Fig. 1). Although patients most likely to benefit from ACE
inhibitors are treated more often, it should be emphasized that
most of these patients still did not receive this life-saving
therapy.
2. Clinicians prescribed ACE inhibitors with increasing
frequency over the 25-month period studied (from 25.0% in
1994 to 30.7% in 1996). This absolute increase of 2.7%/year
represents an 11% relative annual increase. The increase in
ACE inhibitor use over time was observed in all three clinical
indication groups in the multivariate logistic regression model
as well. In contrast, the use of calcium channel blockers fell by
4.2%/year, a 13% relative annual decrease. Interestingly, the
use of a calcium channel blocker was significantly inversely
associated with ACE inhibitor use at discharge in all three
patient groups (Fig. 2). This observation suggests that clini-
cians are becoming increasingly accepting of the data support-
ing the use of ACE inhibitors in patients after AMI.
3. ACE inhibitors were prescribed more often to the
elderly. Patients who received ACE inhibitors were 3 years
older than those who received no therapy at discharge. Multi-
variate logistic regression analysis showed that increasing age
was independently associated with ACE inhibitor use in pa-
tients with a possible indication for ACE inhibitor treatment.
This is in contrast to many other studies that have observed
that therapeutic measures that improve mortality in patients
with myocardial infarction are given less frequently to the
elderly (20–26). For example, treatment of patients with AMI
with thrombolytics, aspirin and beta-blockers significantly de-
creases with advancing patient age (20–26). One possible
explanation why ACE inhibitors are one of the few pharma-
cologic agents used more aggressively in elderly postinfarction
patients is that because these agents have a relatively low
incidence of reported side effects, clinicians feel more comfort-
able prescribing them to elderly patients.
4. We observed that in-hospital PTCA and CABG were
independent predictors of not receiving ACE inhibitor therapy
at discharge. Multivariate logistic regression analysis demon-
strated that CABG was associated with a roughly 50% reduc-
tion in the odds of receiving an ACE inhibitor. This is
surprising because there are insufficient clinical data to suggest
that revascularization attenuates the mortality benefit of ACE
inhibitors. One possible explanation for this finding is that
ACE inhibitors may be less often prescribed by surgeons.
Targeting educational efforts toward surgical or cardiology
consult services may improve utilization of ACE inhibitors in
this group of patients.
5. We also observed that diabetic patients were significantly
more likely to receive ACE inhibitors. One possible explana-
tion for this observation is that ACE inhibitors have been
shown (27,28) to slow the progression of nephropathy in both
insulin-dependent and non–insulin-dependent diabetic pa-
tients.
6. We also observed that simply undergoing echocardiog-
raphy was independently associated with an increased use of
ACE inhibitors in all three groups. We emphasize that this
effect is noted while controlling for LVEF, anterior myocardial
infarction, hypertension, congestive heart failure and the other
variables included in our models. It is possible that obtaining
an echocardiogram reveals other indications for vasodilator
therapy not measured in this study, such as significant mitral or
aortic insufficiency, left ventricular hypertrophy, regional wall
motion abnormalities or aneurysm formation. It is also possi-
ble that clinicians who order echocardiograms are more likely
to translate the information learned from randomized trials to
clinical practice.
Study limitations. The limitations of the National Registry
of Myocardial Infarction 1 registry have been previously de-
scribed (22,29). Significantly more clinical data are now avail-
able for each patient in NRMI 2, such as cardiovascular risk
factors and indicators of infarction size. The major limitation
of the present study is that we did not have information
regarding severity of the major contraindications to therapy,
including renal dysfunction, hyperkalemia, history of bilateral
renal artery stenosis and history of angioedema. We were able
to obtain information regarding renal function for a subset of
patients who were also registered in the CCP database. Using
this data it did not appear that elevated serum creatinine was
a major predictor of not receiving an ACE inhibitor. Another
major contraindication to ACE inhibitor therapy is cardiogenic
shock and persistent hypotension. Although 1% of patients in
our study group had cardiogenic shock on presentation, and
11% had at least one episode of hypotension during their
hospital stay, it is likely that the majority of patients were not
hypotensive at hospital discharge, and therefore these patients
were probably still candidates for long-term ACE inhibitor
therapy.
In addition, we did not collect data regarding whether
patients were not discharged with an ACE inhibitor due to a
previous adverse reaction. Poor patient tolerance of ACE
inhibitor treatment was unlikely to account for the dramatic
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underuse observed in the present study because several ran-
domized clinical trials have shown that ACE inhibitors are well
tolerated by most patients. Rates of withdrawal due to adverse
effects or patient choice are reported to be 10% to 20%
(30,32). For example in ISIS-4, 83% of patients who began
therapy with captopril were discharged with this ACE inhibi-
tor, compared with 87% of patients continuing placebo drug to
discharge (14). A small excess of renal dysfunction was noted
in patients receiving ACE inhibitors in GISSI-3 (2.4% in the
lisinopril group vs. 1.1% in the placebo group) and in ISIS-4
(1.1% in captopril-treated patients vs. 0.6% in placebo pa-
tients) (13,14).
Previous reports of Medicare patients admitted to the
hospital for AMI suggest that of patients .65 years old, 4.9%
had serum creatinine levels $3.0 mg/dl, 0.3% had an allergy to
ACE inhibitors, and overall 8.7% of patients discontinued
ACE inhibitor therapy during their hospital stay (32). Again,
because we found that more than two-thirds of patients in the
present study did not receive this therapy, we conclude that
most patients who did not receive ACE inhibitors probably did
not have a specific contraindication or develop a side effect.
Clinical implications. Current ACC/AHA practice guide-
lines (17) for the management of patients with AMI recom-
mend initiating oral ACE inhibitor therapy within 24 hours of
hospital admission in patients without hypotension or a con-
traindication. The ACE inhibitor should then be continued for
6 weeks for those patients without complications or left
ventricular systolic dysfunction. In patients with impaired
systolic function, ACE inhibitors should be continued indefi-
nitely. Clinical trials have documented (13–15) that initiation
of ACE inhibitor therapy early after myocardial infarction
typically saves five lives per 1,000 patients treated in the first
month. This finding complements the results of other trials
(9,10,12) that have shown that starting long-term ACE inhib-
itor therapy in the weeks after infarction in patients with
impaired ventricular function saves about two lives/1,000 pa-
tients per month of treatment for the first year, or 24 lives/year.
Applying this additive mortality reduction of 29 lives/1,000
patients treated in the first year, if ACC/AHA guidelines had
been used to treat all 75,173 patients in the present study
categorized with the greatest absolute benefit for ACE inhib-
itor use, .1,800 additional lives would have been saved in the
first year alone due to the effect of ACE inhibitors (assuming
15% of patients have a specific contraindication or are intol-
erant of ACE inhibitors) (36).
Conclusions. Although basic and clinical science has had a
profound impact on identifying treatment for patients with
AMI, translating these results into clinical practice is an
equally important goal. NRMI 2 is a unique source of infor-
mation and can be used to assess recent health care trends in
the management of AMI in the United States. Recent data
derived from this registry show trends toward the expanded use
of ACE inhibitors in patients discharged after myocardial
infarction. Although it appears that physicians are increasing
their use of ACE inhibitors in patients discharged after AMI,
far more patients could potentially benefit from this therapy.
Through the analysis of large databases such as NRMI 2 and
with novel educational programs, improvements in the quality
of care of these patients may be attained.
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